Blog: Better to Be Safe Than Sorry When It Comes to Chemical Exposure

09/20/18
I’m fortunate enough to work for a company that recognizes the importance of reducing chemical exposure and equally fortunate to serve in a role where my focus is educating our health care partners about the dangers of chemically laden products. More

Blog: Making the Case for Biosimilars

09/20/18
I recently had the pleasure and privilege to represent Vizient and present at a public hearing by the U.S. Food and Drug Administration (FDA), focused on removing barriers affecting the uptake of biosimilars, which offer a cost savings for some of the most expensive drugs on the market. More

Vizient Provides Valuable Disaster Preparedness Tools

09/20/18
While Florence continues to dump heavy rain on its journey up and ultimately off the eastern shoreline, the worst of her wrath may be behind us for now. But, the storm’s aftermath in the hardest hit areas of the Carolinas has left catastrophic flooding, making major roads impassable and leaving countless people stranded. More

Preparing for the Latest DSCSA Deadline: Are You Ready?

09/20/18
In 2013, the Drug Quality and Security Act (DQSA) was signed into law. Title II of the DQSA, the Drug Supply Chain Security Act (DSCSA), was designed to help ensure the safety and integrity of our nation’s drug supply and to avoid counterfeit medicines from entering the market. More